SCHEMBL378915

SCHEMBL378915

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)c4ccccc4)(c4ccccc4)CC3)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
ATM Q13315 1/20 0.41
SCD5 Q86SK9 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
BDKRB1 P46663 1/20 0.40
ALOX15 P16050 1/20 0.39
ADRB3 P13945 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TBK1 Q9UHD2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396983 0.95 TACR1 (0.40) TSHRATMSCD5CA12CA1
SCHEMBL378669 0.94 TACR1 (0.41) TSHRATMSCD5CA12CA1
SCHEMBL13092272 0.94 TACR3 (0.42) TSHRSCD5CA12CA1CA2
SCHEMBL13092251 0.94 BDKRB1 (0.40) TSHRATMSCD5BDKRB1ADRB3
SCHEMBL13092261 0.93 ALDH1A1 (0.42) TSHRATMSCD5CA12CA1
SCHEMBL395363 0.92 THRB (0.43) TSHRSCD5BDKRB1
SCHEMBL13092253 0.90 TSHR (0.44) TSHRATMSCD5CA12CA1
SCHEMBL379355 0.90 TACR3 (0.41) BDKRB1SLC6A4MEN1KMT2AALDH1A1
SCHEMBL13092246 0.89 TP53 (0.43) TSHRATMSCD5CA12CA1
SCHEMBL379339 0.89 TSHR (0.42) TSHRATMSCD5CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885ATM 2243/4885SCD5 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.